Why GLP-1 drugs work better for some patients than others

What did @wired actually say?

The video makes a reasonable core argument: semaglutide produces highly variable weight loss results, and that variability has identifiable predictors including sex, diabetes status, genetics, and lifestyle habits. The creator says clinical trials show "around a 15% weight loss" and that some people lose "little to no weight" despite consistent use. That framing is broadly accurate, and it's a more honest take on GLP-1 medications than most social media content offers. Still, a few specific claims deserve closer scrutiny.

The creator also explains the mechanism, saying these drugs "mimic GLP-1, a naturally occurring hormone" that slows gastric emptying and acts on brain receptors to promote fullness. They mention sex differences in response, the paradox of lower efficacy in people with type 2 diabetes, and the role of genetics and the microbiome. That's a lot of ground for a short video, and not all of it lands cleanly.

Does the science back this up?

Mostly yes, with some important nuances. The "around 15%" figure comes from the STEP 1 trial (Wilding et al., 2021, NEJM), which found 14.9% mean body weight reduction with 2.4mg semaglutide over 68 weeks. That's a population average, and the distribution matters: roughly 10% of participants lost less than 5% of body weight, while others lost more than 20%. The variability claim is well-supported.

The sex difference claim is backed by a secondary analysis from STEP trials and other GLP-1 research. Women do tend to show greater percentage weight loss, though the mechanism is debated. The diabetes-blunted-response claim is also solid: the STEP 2 trial (Davies et al., 2021, Lancet) found only 9.6% weight loss in people with type 2 diabetes on the same dose, compared to 14.9% in the broader population. Researchers attribute this partly to beta-cell dysfunction, altered gut hormone signaling, and competing medications like insulin or sulfonylureas that promote weight gain.

What did they get wrong (or right)?

The biggest factual slip is describing semaglutide's mechanism as "slowing the movement of food in the stomach." That's technically gastric emptying delay, which is accurate, but the creator frames it as the primary driver of weight loss. That's outdated. Current evidence, including work by Drucker (2022, Cell Metabolism), places the central nervous system effects, particularly hypothalamic appetite suppression, as more significant for weight loss than gastric emptying alone. Framing the stomach-slowing as a lead mechanism slightly misrepresents how these drugs work.

The "food noise" description is colloquial but not inaccurate. It reflects real patient-reported outcomes that have been documented in qualitative research. The lifestyle claim at the end, that these medications are "less effective" without diet and exercise, is accurate and undersold. A 2022 analysis (Blundell et al., NEJM Evidence) showed significantly better outcomes when behavioral intervention was combined with semaglutide. Credit where it's due: the creator avoided the hype trap and framed this as a drug with limits, not a miracle.

What should you actually know?

Response variability on GLP-1 medications is real and clinically significant. Population averages in trials do not predict your individual result. If you are considering semaglutide or any GLP-1 receptor agonist, a few things are worth understanding before you start:

• The 15% average weight loss figure comes from a specific dose (2.4mg weekly) in a specific population. Results at lower doses are more modest.
• People with type 2 diabetes consistently show lower weight loss responses across multiple GLP-1 agents, not just semaglutide.
• Genetic factors influencing GLP-1 receptor expression and gut microbiome composition are active research areas, but no validated clinical test currently predicts individual response before you try the drug.
• Medications that promote weight gain, including some antidepressants, antipsychotics, and insulin formulations, can blunt GLP-1 efficacy. A full medication review before starting matters.
• Lifestyle changes are not optional extras. They are part of how the drug works best. The clinical trials that produced those headline numbers included behavioral counseling components.

If a clinician, influencer, or telehealth platform is promising you a specific outcome number, that's a red flag. Individual response depends on factors that are still not fully understood.